FDA warns Lux Therapeutics over unvalidated TheraMend amniotic patches and records, citing inadequate response and Luxegen distribution concerns.
What happened
FDA inspected the Brookhaven, GA facility June 2–6, 2025 and issued a Form FDA 483 listing inspection observations. FDA found the firm processed and distributed TheraMend, a human cell/tissue product (HCT/P), since August 2023 without a validated manufacturing process, and that accompanying records lacked a summary of communicable disease test results. FDA also called the firm’s June 30, 2025 response inadequate and raised concerns about continued distribution of Luxegen until December 1, 2025, citing lack of approval and manufacturing conditions.
What FDA found
The firm did not validate the TheraMend manufacturing process, which cannot be fully checked later, and it processed and distributed TheraMend without a validated process since August 2023.
21 CFR 1271.230(a)The firm’s accompanying records for the HCT/P did not include a summary listing and interpreting all communicable disease test results.
21 CFR 1271.55(b)(2)FDA asked that a statement of donor eligibility or ineligibility accompany the HCT/P once a donor-eligibility determination is made.
21 CFR 1271.55(a)(2)
What FDA wants
FDA asks for a written response within 15 working days with specific corrective steps and documentation. FDA also asks for plans for Luxegen remaining in the marketplace, confirmation that distribution ceased by December 1, 2025, and changes to address TheraMend distribution until validation and product already distributed.
Who should pay attention
- clinics and clinicians implanting amniotic membrane patches
- distributors and buyers of TheraMend or Luxegen
- companies relying on HCT/P donor and processing records
This is a summary. Read the original letter on fda.gov.